Clinical trials: SC Disease
Inflammatory Bowel Disease (IBD), Crohn's Disease
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland
The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
- Trial name
- VARIETY (NCT05384080)
- Where
- 11 sites in Poland
- Volunteers
- 165 people
- Sponsor
- Takeda
Anemia, Solid Tumors
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
The purpose of this study is to assess the safety of NESP administered by SC injection in subjects with solid tumours and anaemia receiving multicycle chemotherapy.
- Trial name
- NCT00540384
- Testing
- Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
- Volunteers
- 405 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to…
- Trial name
- NCT04179032
- Testing
- Belimumab
- Where
- 11 sites in United States, Argentina and 5 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Healthy Volunteers
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.
- Trial name
- NCT06103877
- Testing
- AZD1163
- Where
- 3 sites in United States, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus
Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler
Evaluation of the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered…
- Trial name
- NCT00426920
- Testing
- Insulin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- QDose Limited
Prostate Cancer
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in…
- Trial name
- PAMIS (NCT01257425)
- Testing
- Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
- Where
- 22 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Ipsen
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Heart Failure
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in…
- Trial name
- NCT02808585
- Testing
- PB1046 Injection
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion
Alpha 1 Antitrypsin Deficiency
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standard doses of the same medicine given through a vein.
- Trial name
- SWIFT-SC (NCT07555483)
- Testing
- Alpha-1 15%, Liquid Alpha1-PI
- Where
- 22 sites in United States, Denmark and 7 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Multiple Myeloma
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with…
- Trial name
- MajesTEC-3 (NCT05083169)
- Testing
- Daratumumab, Pomalidomide, Dexamethasone
- Where
- 176 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- Janssen Research & Development, LLC
Parkinson's Disease
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant…
- Trial name
- NCT02096601
- Testing
- LD/CD SC solution, Entacapone
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- NeuroDerm Ltd.
Multiple Sclerosis
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif®…
- Trial name
- NCT00958009
- Testing
- Rebidose®
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- EMD Serono
Healthy Volunteers
Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.
A study to evaluate and compare the PK profiles of abaloparatide-SC 80 μg and abaloparatide-sMTS 300 μg in a cohort of healthy men and to make a similar evaluation in a cohort of healthy women
- Trial name
- NCT04663464
- Testing
- abaloparatide-sMTS, abaloparatide-SC
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Radius Health, Inc.
Osteoporosis, Osteoporosis, Age-Related
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis
- Trial name
- NCT03512262
- Testing
- Abaloparatide
- Where
- 34 sites in United States, Italy and 1 more
- Volunteers
- 228 people
- Sponsor
- Radius Health, Inc.
Breast Cancer
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
This prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab (Herceptin) SC and IV formulations in HER2-positive EBC.
- Trial name
- NCT02658461
- Testing
- Trastuzumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Hypercholesterolemia
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects
Primary Objective: To assess the safety and tolerability of ascending single SC doses of alirocumab in Chinese healthy subjects. Secondary Objectives: To assess the pharmacokinetic profile of a single SC dose of alirocumab.
- Trial name
- NCT02979015
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Systemic Lupus Erythematosus
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
- Trial name
- PEARL-SC (NCT01162681)
- Testing
- A-623
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 547 people
- Sponsor
- Anthera Pharmaceuticals